Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Cisplatin is a chemotherapeutic drug used to treat a variety of cancers. Both intrinsic and acquired resistance to cisplatin, as well as toxicity, limit its effectiveness. Molecular mechanisms that underlie cisplatin resistance are poorly understood. Here we demonstrate that deletion of the yeast CTR1 gene, which encodes a high-affinity copper transporter, results in increased cisplatin resistance and reduced intracellular accumulation of cisplatin. Copper, which causes degradation and internalization of Ctr1 protein (Ctr1p), enhances survival of wild-type yeast cells exposed to cisplatin and reduces cellular accumulation of the drug. Cisplatin also causes degradation and delocalization of Ctr1p and interferes with copper uptake in wild-type yeast cells. Mouse cell lines lacking one or both mouse Ctr1 ( mCtr1 ) alleles exhibit increased cisplatin resistance and decreased cisplatin accumulation in parallel with mCtr1 gene dosage. We propose that cisplatin uptake is mediated by the copper transporter Ctr1p in yeast and mammals. The link between Ctr1p and cisplatin transport may explain some cases of cisplatin resistance in humans and suggests ways of modulating sensitivity and toxicity to this important anticancer drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longtine, M. S., Mckenzie III, A., Demarini, D. J., Shah, N. G., Wach, A., Brachat, A., Philippsen, P., & Pringle, J. R. (1998) · Yeast · doi:10.1002/(sici)1097-0061(199807)14:10<953::aid-yea293>3.0.co;2-u · Cited by 5,345
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
LOEHRER, P. J., & EINHORN, L. H. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-5-704 · Cited by 947
Dancis, A., Yuan, D. S., Haile, D., Askwith, C., Eide, D., Moehle, C., Kaplan, J., & Klausner, R. D. (1994) · Cell · doi:10.1016/0092-8674(94)90345-x · Cited by 659
Biochemical Characterization of the Human Copper Transporter Ctr1
Lee, J., Peña, M. M. O., Nose, Y., & Thiele, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104728200 · Cited by 608
Self-citationCellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
h CTR1: A human gene for copper uptake identified by complementation in yeast
Zhou, B., & Gitschier, J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7481 · Cited by 567
Cisplatin and DNA repair in cancer chemotherapy
Zamble, D. B., & Lippard, S. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89095-7 · Cited by 538
Burns, N., Grimwade, B., Ross-Macdonald, P. B., Choi, E. Y., Finberg, K., Roeder, G. S., & Snyder, M. (1994) · Genes & Development · doi:10.1101/gad.8.9.1087 · Cited by 490
Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development
Lee, J., Prohaska, J. R., & Thiele, D. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111058698 · Cited by 472
Self-citation
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
“Ishida et al. (2002) demonstrated that uptake of cisplatin is mediated by the copper transporter Ctr1 in yeast and mammals.”
BackgroundNew metal complexes as potential therapeutics
Zhang, C. X., & Lippard, S. J. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00081-4 · Cited by 946
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
“Cisplatin (cis-diammine-dichloroplatinum (II), cDDP, cis-PtCl2(NH3)2) enters the cells ether through passive diffusion or by active transport by Ctr1 (copper transporter 1) [70] or Oct2 (organic cation transporter 2) [71].”
BackgroundHuman kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment
Jang, K.-J., Mehr, A. P., Hamilton, G. A., McPartlin, L. A., Chung, S., Suh, K.-Y., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40049b · Cited by 849
Targeting copper in cancer therapy: ‘Copper That Cancer’
Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015) · Metallomics · doi:10.1039/c5mt00149h · Cited by 806
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Pathophysiology of Cisplatin-Induced Acute Kidney Injury
Ozkok, A., & Edelstein, C. L. (2014) · BioMed Research International · doi:10.1155/2014/967826 · Cited by 703
Cisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
Mechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Platinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Copper in the brain and Alzheimer’s disease
Hung, Y. H., Bush, A. I., & Cherny, R. A. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0600-y · Cited by 498
Platinum Complexes as Anticancer Agents
Kostova, I. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206775246458 · Cited by 493
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., & Yu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00343 · Cited by 479
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Metal complex interactions with DNA
Pages, B. J., Ang, D. L., Wright, E. P., & Aldrich-Wright, J. R. (2015) · Dalton Transactions · doi:10.1039/c4dt02700k · Cited by 459
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R. (2019) · Cancer Medicine · doi:10.1002/cam4.2560 · Cited by 449
Lazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 428
New Roles for Copper Metabolism in Cell Proliferation, Signaling, and Disease
Turski, M. L., & Thiele, D. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800055200 · Cited by 422
Self-citationBioavailable copper modulates oxidative phosphorylation and growth of tumors
Ishida, S., Andreux, P., Poitry-Yamate, C., Auwerx, J., & Hanahan, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318431110 · Cited by 422
Self-citationStructural Biology of Copper Trafficking
Boal, A. K., & Rosenzweig, A. C. (2009) · Chemical Reviews · doi:10.1021/cr900104z · Cited by 420
How do chemotherapeutic agents damage the ovary?
Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H., & Spears, N. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms022 · Cited by 409
Molecular mechanisms of cisplatin resistance in cervical cancer
Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s106412 · Cited by 407
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
Romani, A. M. P. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 383
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
dos Santos, N. A. G., Carvalho Rodrigues, M. A., Martins, N. M., & dos Santos, A. C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0821-7 · Cited by 378
Copper metabolism as a unique vulnerability in cancer
Shanbhag, V. C., Gudekar, N., Jasmer, K., Papageorgiou, C., Singh, K., & Petris, M. J. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118893 · Cited by 368
McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli, A., & Apostolopoulos, V. (2021) · Cancers · doi:10.3390/cancers13071572 · Cited by 363
Cisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Platinum Drug Distribution in Cancer Cells and Tumors
Klein, A. V., & Hambley, T. W. (2009) · Chemical Reviews · doi:10.1021/cr9001066 · Cited by 351
Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Schacht, J., Talaska, A. E., & Rybak, L. P. (2012) · The Anatomical Record · doi:10.1002/ar.22578 · Cited by 348
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Generation of kidney organoids from human pluripotent stem cells
Takasato, M., Er, P. X., Chiu, H. S., & Little, M. H. (2016) · Nature Protocols · doi:10.1038/nprot.2016.098 · Cited by 342
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, G. Y., Woodward, N., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.014 · Cited by 325
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy
Dasari, S., Njiki, S., Mbemi, A., Yedjou, C. G., & Tchounwou, P. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031532 · Cited by 308
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 288
Self-citationRole of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90545.2008 · Cited by 283
The roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
Arnesano, F., & Natile, G. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.01.028 · Cited by 282
Three-dimensional structure of the human copper transporter hCTR1
De Feo, C. J., Aller, S. G., Siluvai, G. S., Blackburn, N. J., & Unger, V. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810286106 · Cited by 276
Human Copper Transporters: Mechanism, Role in Human Diseases and Therapeutic Potential
Gupta, A., & Lutsenko, S. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.84 · Cited by 275
Song, I.-S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., & Kuo, M. T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1543.3.12 · Cited by 259
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
Safaei, R., & Howell, S. B. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.007 · Cited by 254
Ortega, R., Devès, G., & Carmona, A. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2009.0166.focus · Cited by 150
“1996), which can be linked to the expression of copper transport proteins in cisplatin-resistant cells (Ishida et al. 2002).”
BackgroundHerraez, E., Gonzalez-Sanchez, E., Vaquero, J., Romero, M. R., Serrano, M. A., Marin, J. J. G., & Briz, O. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300178a · Cited by 67
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
Metadata
- Authors
- Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-10-07
- Volume
- 99
- Issue
- 22
- Pages
- 14298-14302
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2084492467
- Cited by
- 927
- References
- 33
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.